Haemonetics Corporation: Q3 Fiscal 2008 Summary (Period Ended Dec 29, 2007)
Business Context and Reporting Period
This Form 10-Q covers the third quarter and first nine months of Haemonetics Corporation's fiscal year 2008, ended December 29, 2007. Haemonetics designs, manufactures, and markets automated blood management systems for donor and patient care, including equipment, disposables, and software solutions. The company operates globally with significant revenue exposure to the Euro and Japanese Yen.
Key Financial Metrics
| Metric (in thousands) | Q3 FY08 | Q3 FY07 | 9M FY08 | 9M FY07 |
|---|---|---|---|---|
| Net Revenues | $134,587 | $113,527 | $377,701 | $332,688 |
| Gross Profit | $66,558 | $56,419 | $187,940 | $168,953 |
| Gross Margin | 49.5% | 49.7% | 49.8% | 50.8% |
| Operating Income | $19,597 | $17,005 | $49,990 | $37,052 |
| Net Income | $14,354 | $16,902 | $38,199 | $29,324 |
| Diluted EPS | $0.54 | $0.62 | $1.43 | $1.06 |
| Cash & Equivalents | $116,857 | $229,227 (Mar 31, 2007) | N/A | |
| Total Debt | $12,408 | $28,876 (Mar 31, 2007) | N/A | |
| Operating Cash Flow (9M) | N/A | $45,754 | $59,467 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.6% in Q3 and 13.5% year-to-date (YTD). Growth was driven by organic increases in disposables and equipment sales, favorable foreign exchange rates (+4.2% impact in Q3), and the acquisition of Haemoscope Corporation in November 2007.
- Profitability: Operating income rose 15.2% in Q3 and 34.9% YTD. However, Q3 net income decreased 15.1% due to a higher effective tax rate (31.3% vs. 12.9% in prior year) driven by discrete tax items and the expiration of statute of limitations benefits in the prior year.
- Acquisitions: The company acquired Haemoscope's TEG business for $45 million and Infonale, Inc. for $1.3 million. These acquisitions contributed to revenue growth and increased goodwill and intangible assets.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 23.3% in Q3, largely due to acquisition integration costs and ERP implementation expenses. Research and development (R&D) expenses decreased 4.7% in Q3.
- Liquidity: Cash and cash equivalents decreased from $229.2 million to $116.9 million. This reduction was primarily due to $75.0 million in share repurchases, $46.4 million in acquisition costs, and increased capital expenditures ($42.5 million).
Guidance, Outlook, and Risks
- Tax Outlook: Management expects the annual tax rate for fiscal 2008 to be approximately 35.1%, with a full-year reported rate between 32% and 33% due to discrete items.
- Restructuring: The company is consolidating European customer support functions in Switzerland, expecting to incur $4 million to $5 million in exit costs, with annual operating savings of approximately $1.5 million.
- ERP Implementation: Phase I of the Oracle ERP implementation was completed in the U.S. in Q3. The company anticipates continued costs and process changes as the system rolls out globally.
- Foreign Exchange: Approximately 55% of sales are generated outside the U.S. The company uses forward contracts to hedge currency exposure, but results remain sensitive to fluctuations in the Euro and Japanese Yen.
- Risks: Key risks include regulatory uncertainties, market acceptance of new products, competitive pricing pressures, and the impact of industry consolidation in the plasma market.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration progress of the Haemoscope and Infonale acquisitions.
- Share Repurchase Impact: Assess the impact of the $75 million share repurchase program on liquidity and future capital allocation.
- Tax Rate Volatility: Monitor the effective tax rate for the remainder of fiscal 2008, given the discrete items affecting the current quarter.
- ERP Costs: Track ongoing capital expenditures and operating costs related to the global ERP implementation.
- Foreign Exchange Sensitivity: Evaluate the company's hedging strategy effectiveness against recent currency fluctuations.